Md. Wood et al., The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen, BR J PHARM, 131(6), 2000, pp. 1050-1054
1 The aim of this study was to characterize the pharmacological profile of
the GABA(B1)/GABA(B2) heterodimeric receptor expressed in Chinese hamster o
vary (CHO) cells. We have compared receptor binding affinity and functional
activity for a series of agonists and antagonists.
2 The chimeric G-protein, G(qi5), was used to couple receptor activation to
increases in intracellular calcium for functional studies on the Fluorimet
ric Imaging Plate Reader (FLIPR), using a stable GABA(B1)/GABA(B2)/G(qi5) C
HO cell line. [H-3]-CGP-54626 was used in radioligand binding studies in me
mbranes prepared from the same cell line.
3 The pharmacological profile of the recombinant GABA(B1/B2) receptor was c
onsistent with that of native GABAB receptors in that it was activated by G
ABA and baclofen and inhibited by CGP-54626A and SCH 50911.
4 Unlike native receptors, the GABA(B1)/GABA(B2)/G(qi5) response was not in
hibited by high microMolar concentration of phaclofen, saclofen or CGP 3534
8.
5 This raises the possibility that the GABA(B1)/GABA(B2)/G(qi5) recombinant
receptor may represent the previously described GABAB receptor subtype whi
ch is relatively resistant to inhibition by phaclofen.